CD274 and non-small cell lung carcinoma: NCT06623136 is an upcoming study of the combination of Toripalimab (an ICI) in combination with ES102 (an OX40 agonist) for patients with unresectable locally advanced and metastatic non-small cell lung cancer not suitable for radical concurrent chemoradiotherapy and PD-L1 TPS ≥ 50%.